The early patient trial results are only known to the company running the trial - not BNO - which I believe is arms length from BNO.
So, the company would not likely have much if any insight as to how the trials have gone in respect to those that were enrolled early and who have completed their assessments.
Anyway, BNO is not exactly renowned for the clarity of its announcements.
Wait and see......................
More interesting will be when we see how many options the Board awards the CEO for her glorious achievements this year - and that will be very interesting as there are no commercial successes to justify any payments at all......................
It would be wonderful to know what criteria they use for the award of such benefits.
Especially given the excessively generous base pay.
She has had a good stay at the trough - but if this PTSD trial is not a roaring success, then she will need to hope off the gravy train!!!
GLTA
BNO Price at posting:
50.5¢ Sentiment: None Disclosure: Held